NCT05468645 is a Phase 1 clinical trial of [14C]Hemay005 in Health Volunteer, sponsored by Ganzhou Hemay Pharmaceutical Co., Ltd.

Who is sponsoring NCT05468645?

NCT05468645 is sponsored by Ganzhou Hemay Pharmaceutical Co., Ltd.

What drugs are being tested in NCT05468645?

Interventions in NCT05468645: [14C]Hemay005.

What condition does NCT05468645 study?

NCT05468645 studies Health Volunteer.

Is NCT05468645 still recruiting?

NCT05468645 is currently completed. Last updated 29 February 2024.

Last reviewed 2024-02-29 · How we verify

NCT05468645

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

In Vivo Mass Balance Study of [14C]Hemay005

Completed Phase 1 Last updated 29 February 2024

What this trial tests

Phase 1 trial testing [14C]Hemay005 in Health Volunteer in 6 participants. Completed in 1 September 2022.

Timeline

25 July 2022

Primary endpoint
1 September 2022

1 September 2022

Quick facts

Lead sponsor	Ganzhou Hemay Pharmaceutical Co., Ltd
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	6
Start date	25 July 2022
Primary completion	1 September 2022
Estimated completion	1 September 2022
Sites	1 location across China

Drugs / interventions tested

[14C]Hemay005 — full drug profile →

Conditions studied

Health Volunteer — all drugs for Health Volunteer →

Sponsor

Ganzhou Hemay Pharmaceutical Co., Ltd — full company profile →

Who can join

Adults 18 to 40, male only, with Health Volunteer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a single-center, single-dose, non-randomized, open-label study to evaluate the in vivo mass balance of \[14C\]Hemay005. Six healthy male subjects are planned to be enrolled.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Health Volunteer

Currently open trials in the same condition.

NCT05256719 — Clinical Study of Recombinant Humanized CTLA-4-FC Fusion Protein Injection in Healthy Subjects · Phase 1 · recruiting

Other Ganzhou Hemay Pharmaceutical Co., Ltd trials

Trials by the same sponsor.

NCT07314242 — A Study to Investigate the Biomarkers of Hemay005 in Adult Participants With Moderate to Severe COPD · Phase 2 · not yet recruiting
NCT06610890 — Pharmacokinetic Interactions Between Hemay005 Tablets and Midazolam Maleate Tablets · Phase 1 · completed
NCT06610903 — Bioequivalence Test of Hemay005 Tablets · Phase 1 · completed
NCT06380153 — To Evaluate the Pharmacokinetics of Hemay005 Tablets in Patients With Renal Impairment · Phase 1 · completed
NCT06376474 — To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05468645 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ganzhou Hemay Pharmaceutical Co., Ltd
Last refreshed: 29 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05468645.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing